Q4 FY2026 EarningsFY26 Q4 results slightly beat consensus on the top line with revenue of $36.36B vs. $36.12B expected, though normalized EPS of $5.53 was largely in-line with the $5.52 mean. Cardiovascular was the strongest performer, growing 12% YoY, while the non-reportable Diabetes segment surged 13% ahead of its planned full separation. Guidance remains cautious as management flagged a $250M headwind from anticipated tariffs in FY27.
Financial report interval: 2026.01.30 - 2026.04.30
Overview: Medtronic(MDT) the Revenue is 9.807 B (+9.86%), Beat estimate;the EBIT is 2.5 B (+0.56%), Miss estimate;the EPS is 0.96 (+17.07%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
9.81B9.86%
9.61B7.68%
+0.19B2.18%
EBITMiss expectations
2.50B0.56%
2.59B4.37%
-0.09B3.81%
EPSMiss expectations
0.9617.07%
1.180743.98%
-0.220726.91%
Upcoming earnings report - FY2027 Q1 Earning Release
Available dateSep 1, 2026
Estimate Revenue9.545 B
Estimate EBIT2.263 B
Estimate EPS1.0002
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf